Independent audit will verify company's compliance
INDIANAPOLIS, July 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced its support of the Pharmaceutical Research and Manufacturers of America (PhRMA) revised Code on Interactions with Healthcare Professionals (Code). As a part of its support, Lilly will commit to act in accordance with, or exceed, the new Code in its interactions with healthcare professionals. Moreover, Lilly will implement periodic external verification to ensure that the company has policies and procedures in place to foster compliance with the Code.
Lilly's support coincides with today's announcement by PhRMA, whose Board of Directors approved the revised Code at its June 2008 meeting. Lilly is a member of PhRMA and played an active role in driving the Code revisions.
"Our sales representatives are a valuable resource to healthcare professionals, informing them about the scientific advancements in medicine," said Robert Brown, chief marketing and operations officer for Lilly's U.S. operations. "We believe that the meaningful Code revisions that have been adopted will address the concerns of our various stakeholders and strengthen the public trust in our industry."
"Lilly believes the revised Code will help to ensure that the information exchange with healthcare providers continues to be appropriate and ethical," said Brown.
The new Code will set a new standard for appropriate sales and marketing practices, while codifying many of the practices already common within the industry. Some of the changes include, but are not limited to, the following:
-- Limits meals to modest, occasional, in-office with informational presentations. Allows outside meals only in conjunction with speaker or peer selling programs.
-- Promotional gifts, such as pens and notepads, will no longer be allowed. No items can be given to healthcare providers unless they are educational in nature such as anatomical models, textbooks or patient self-assessment and tracking tools.
-- Establishes a public website that will identify companies who commit to abide by the Code, provides contract information for the Chief Compliance Officers, and publishes the status of each company's annual certification.
The new Code takes effect in January 2009, and Lilly will begin implementing the changes in the coming months.
"Moving forward, Lilly will strive to attain even higher standards in our interactions with healthcare professionals," said Brown. "Our marketing representatives will continue to serve as an important connection point with our customers -- delivering reliable information about scientific advancements and new therapies that help healthcare professionals understand which treatments are appropriate for their patients."
Lilly's participation in developing and supporting PhRMA's revised Code aligns with the company's agenda to build greater public confidence through transparency of its business. In 2004, Lilly became the first company to voluntarily make public its clinical trials and its clinical trials data; that information can be found at http://www.lillytrials.com . And last year Lilly added another first by publicly reporting all of its educational grants and charitable contributions and, each quarter, posting the data online at http://www.lillygrantoffice.com . In May, Lilly became the first pharmaceutical research company to support the Physicians Payments Sunshine Act. The bipartisan bill would establish a national registry of payments to physicians by medical device, medical supply and pharmaceutical companies.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. C-LLY
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved